admin
The new release of internal emails from May 2021 puts a fresh spotlight on how federal health agencies handled early warnings about unusual post‑COVID‑vaccine complaints. The memo, sent by then‑Acting FDA Commissioner Janet Woodcock and forwarded by Dr. Anthony Fauci, warned that people were reporting persistent, hard‑to‑measure symptoms after vaccination. Fauci’s short note on the message — “We cannot ignore her” — now reads like a promise that was never kept.
The email that changed the conversation
The document made public by Senate investigators shows Janet Woodcock telling NIH and NIAID leadership that she had fielded “a number of people who have experienced adverse events post COVID‑19 vaccination.” She said the complaints didn’t fit a neat pattern, were hard to test for, and that “no one takes them seriously.” Dr. Fauci forwarded the note to then‑NIH Director Francis Collins and added, “We cannot ignore her. We should probably bring in CDC and see what Rochelle thinks.” That exchange, released as part of the Senate Permanent Subcommittee on Investigations’ files, is now a primary source for questions the public needs answered.
What Woodcock actually urged — and why it matters
Woodcock wasn’t whispering a conspiracy. She argued for studies into the complaints and warned that industry would likely not fund the research. Her warning was plain: let the problem fester and it will “come back to bite you later.” She also warned federal surveillance tools might miss these cases because many symptoms were not easily quantifiable and could be masked by the flood of COVID vaccine reports. That is not hype. It is a sober admission from a career regulator that the system may have blind spots.
Fauci’s line and the follow‑through that never came
So Fauci agreed it couldn’t be ignored. Then what? The public record released so far does not show a clear, dedicated study launched in response to Woodcock’s note, or a documented, transparent path showing CDC was brought in and acted. Meanwhile, some signals — like myocarditis — were reviewed openly around the same time. But Woodcock’s broader plea for independent study of hard‑to‑classify complaints seems to have been relegated to memos and committee files while many Americans kept waiting for answers. That mismatch between words and action is where accountability must live.
Conclusion: demand transparency, not talking points
The newly released email is a simple, powerful fact: a senior FDA official raised a red flag and a top federal scientist said it couldn’t be ignored. The public deserves to know exactly what happened next. Which agencies were contacted? What studies were launched? Why were long‑standing surveillance weaknesses allowed to persist? If federal health leaders truly want trust, they will open the books, explain the timeline, and fund the research Woodcock urged. Anything less is just another bureaucratic shrug with clean talking points and no answers.
